Publication: Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
Issued Date
2001-02-10
Resource Type
ISSN
01695002
Other identifier(s)
2-s2.0-0035139474
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Lung Cancer. Vol.31, No.2-3 (2001), 257-265
Suggested Citation
Vorachai Ratanatharathorn, Vicharn Lorvidhaya, Savitree Maoleekoonpairoj, Pramook Phromratanapongse, Suwannee Sirilerttrakul, Puangthong Kraipiboon, Arkom Cheirsilpa, Saipin Tangkaratt, Vichien Srimuninnimit, Pitayapoon Pattaranutaporn Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer. Vol.31, No.2-3 (2001), 257-265. doi:10.1016/S0169-5002(00)00171-9 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26846
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
Other Contributor(s)
Abstract
We conducted a phase II trial to investigate the efficacy of concurrent chemoradiation in patients with stage III non-small-cell lung cancer (NSCLC). Thirty patients with inoperable NSCLC were enrolled onto a multicenter phase II trial of concurrent chemoradiation therapy. Patients received six weekly cycles of paclitaxel 45 mg/m2over 1 h; carboplatin at (area under the curve) AUC 2; and radiation therapy of 60 Gy. Radiation was administered to the primary tumor and regional lymph nodes (40 Gy over 4 weeks) followed by a boost to the primary tumor (20 Gy in 2 weeks). After the initial phase of concurrent chemoradiation, patients received an additional four cycles of paclitaxel 175 mg/m2over 3 h and carboplatin at AUC 6 every 3 weeks. The overall objective response rate of 30 assessable patients was 76.7%. At the median follow-up time of 13.1 months, the median survival time was 14.5 months (95% CI, 10.59-18.48). The median progression-free survival was 10.5 months (95% CI, 7.72-13.28). The major toxicity was hematologic. The incidence of grade 3 esophagitis was 10%. In conclusion, this chemoradiation regimen is well tolerated and shows significant clinical results for locally advanced NSCLC. Locoregional failure rate remains an important issue with this newer chemotherapeutic regimen. A novel chemotherapy and radiation therapy is clearly needed. Copyright © 2001 Elsevier Science Ireland Ltd.